Articles tagged "Liver transplantation"

2015 American Transplant Congress
The Predictive Value of the Proliferation Marker Ki-67 in Patients With Fulminant Hepatic Failure
A. Shah,¹ U. Joneja,² D. Walls,¹ J. Farber.²
¹Surgery, Thomas Jefferson University, Philadelphia, PA; ²Pathology, Thomas Jefferson University, Philadelphia, PA.
This study aimed to evaluate the prognostic significance of the cellular proliferation marker Ki-67 in the liver biopsies of patients with fulminant hepatic failure.Under IRB…
2015 American Transplant Congress
Use of MELD Exception Points in Patients With Hepatic Neuroendocrine Tumor Metastases: Variable Use and Proposed Criterion for Approval
Y. Nobel,¹ D. Goldberg.^2,3,4
¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ²Division of Gastroenterology, Department of Medicine, University of Pennsylvania, Philadelphia, PA; ³Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; ⁴Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA.
Purpose: Most patients with metastatic neuroendocrine tumors (NETs) have preserved hepatic synthetic function, and their providers may seek increased waitlist priority via MELD exception points.…
2015 American Transplant Congress
Cost-Effective, Simple PTC Tasting Could Be a Useful Adjunct to Selection Criteria of ARLD Patients
K. Bortecen,¹ D. Freitas,¹ C. Teperman,² M. Hamshow,¹ B. Gelb,¹ G. Morgan,¹ L. Teperman.¹
¹Transplant Surgery, NYU Langone Medical Center, The Mary Lea Johnson Richards Organ Transplant Center, New York, NY; ²Columbia Prep School, New York, NY.
Purpose: Phenylthiocarbamide (PTC) tasting has been linked to alcohol use. The bitter taste for PTC is mediated by TAS2R38 gene. We have previously shown individuals…
2015 American Transplant Congress
Liver Transplantation for Primary Liver Malignancies Vs. Neuroendocrine Metastases: Analysis of the UNOS Dataset
V. Vilchez,¹ M. Shah,¹ M. Daily,¹ S. Krohmer,² D. Davenport,¹ E. Maynard,¹ R. Gedaly.¹
¹Department of Surgery - Transplant Section, University of Kentucky, Lexington, KY; ²Department of Radiology, University of Kentucky, Lexington, KY.
Objective: To determine outcome in patients undergoing LT for NETs, and compared them with outcomes in patients with primary liver malignancies such as Hepatocellular Carcinoma…
2015 American Transplant Congress
Preemptive Therapy for Cytomegalovirus Disease in Liver Transplant Recipients-A Single Center Experience
N. Alvey,¹ J. Tieman,¹ A. Diamond,² A. Hodowanec,¹ D. Simon,¹ S. Fayek,¹ M. Hertl,¹ O. Olaitan,¹ E. Hollinger,¹ E. Chan.¹
¹Rush University Medical Center, Chicago, IL; ²Lahey Hospital and Medical Center, Boston, MA.
Background: Cytomegalovirus (CMV) is a common opportunistic infection after liver transplantation and is associated with significant morbidity and mortality. There are two strategies for preventing…
2015 American Transplant Congress
Interventional Treatment With Minimal Surgery Is an Effective Way for Acute Portal Vein Thrombosis After Pediatric Liver Transplantation: The Experience of Largest Pediatric Liver Transplantation Center in China
Y. Liu,¹ T. Lu,¹ C. Shen,¹ Q. Xia,¹ Y. Luo,¹ T. Zhou,¹ B. Qiu,¹ M. Zhang,¹ L. Han,¹ Q. Chen.²
¹Department of Liver Surgery, Renji Hospital, Shanghai, China; ²Department of Pediatric Surgery, Shanghai Children Medical Center, Shanghai, China.
Purpose: The purpose of this study was to evaluate the prognosis of interventional treatment through inferior mesenteric vein (IMV) and other treatments systemically for acute…
2015 American Transplant Congress
Efficacy of Low Dose Chemoprophylaxis for Coccidioidomycosis Infection in Liver Transplantation Recipients
R. El Ramahi,² S. Habib,¹ S. Rosen,³ S. Farran,³ C. Walker,³ J. Shubeilat,⁴ S. Yost,⁵ O. McCotter,⁶ M. Cassal,⁶ A. Rana,⁷ T. Boyer,¹ T. Zangeneh.²
¹Liver Research Institute, Divisions of Gastroenterology, Hepatology and Transplantation, Department of Medicine, University of Arizona, Tucson, AZ; ²Division of Infectious Disease, Department of Medicine, University of Arizona, Tucson, AZ; ³Internal Medicine Residency Program, Department of Medicine, University of Arizona, Tucson, AZ; ⁴Division of Infectious Disease, Department of Medicine, University of Massachusetts, Worcester, MA; ⁵Division of Transplantation, School of Pharmacy, University of Arizona, Tucson, AZ; ⁶Office of Border Health, Arizona Department of Health Services, Tucson, AZ; ⁷Division of Transplantation, Department of Surgery, University of Arizona, Tucson, AZ.
Introduction:Coccidioidomycosis(CM) infection rate of 6.9% has been reported in solid organ transplantation recipients living in endemic Southwestern U.S.Aim:Assess the risk of CM infection in liver…
2015 American Transplant Congress
The Extended Toronto Criteria for Transplantation for Hepatocellular Carcinoma. A Validation Study
G. Sapisochin, N. Goldaracena, J. Laurence, M. Dib, A. Barbas, A. Ghanekar, L. Lilly, E. Renner, M. Selzner, M. Cattral, I. McGilvray, D. Grant, P. Greig.
Multi-Organ Transplant, Toronto General Hospital. University of Toronto, Toronto, ON, Canada.
Liver transplant (LT) listing criteria for patients with hepatocellular cancers (HCC) that exceed the Milan criteria are still controversial. At the University of Toronto, we…
2015 American Transplant Congress
Changes in Acceptances Patterns Under Share 35
K. Washburn, E. Edwards, A. Harper.
University of Texas HSC, San Antonio, TX; UNOS, Richmond, VA.
The Share 35 policy was implemented June 2013 with intent of directing to livers to the sickest patients with the highest mortality and presumably shortest…
2015 American Transplant Congress
High Tolerability With Sofosbuvir-Based Direct-Acting Antiviral Therapy in Liver Transplant Recipients With Recurrent Hepatitis C
B. Osborne,¹ A. Modi,¹ M. Gautam,¹ N. Murray,¹ I. Gonzalez,² J. McAfee,² S. Gonzalez.¹
¹Hepatology, Baylor Simmons Transplant Institute, Fort Worth, TX; ²Hepatology, Liver Consultants of Texas, Fort Worth, TX.
Background: Reports on efficacy, safety, and tolerability of sofobuvir-based antiviral regimens in liver transplant recipients with recurrent hepatitis C are limited. Methods: We performed a…